Three decades of improvement in posttransplant outcomes for primary refractory and first relapsed cHL. (A) Freedom from treatment failure (FFTF) following conventional chemotherapy with dexa-BEAM or high-dose chemotherapy with BEAM followed by autologous stem cell transplantation (BEAM-HSCT). (Reprinted from Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065-2071, with permission from Elsevier.) (B) Progression-free survival after PET-adapted therapy with ICE and GVD (green) or BV and ICE (blue) followed by AHCT (curves updated from references 12 and 13). (C) Progression-free survival after pembro-GVD followed by AHCT (curve updated from reference 16).